Veru doubles cash position, secures FDA pathway for obesity drug
Operating loss narrows 47% as biotech prepares Phase 2b PLATEAU trial with tirzepatide combination
Veru Inc. more than doubled its cash reserves and narrowed its operating loss by nearly half in the fiscal first quarter, as the clinical-stage biotechnology company prepares to launch a pivotal trial of its muscle-preserving obesity treatment alongside blockbuster weight-loss drugs.
The Miami-based company reported a net loss of $0.26 per share for the quarter ended December 31, beating the consensus estimate of a $0.47 loss, according to MarketBeat. Operating loss from continuing operations declined to $5.4 million from $10.2 million in the prior-year period, a 47% improvement that reflects disciplined cost management as the company advances its clinical pipeline.
Most significantly, Veru's cash position surged to $33 million from $15.8 million at the end of the prior quarter, the company disclosed in its earnings release. The strengthened balance sheet provides runway for the Phase 2b PLATEAU clinical trial, which is scheduled to begin this quarter.
The FDA has provided Veru with crucial regulatory clarity for enobosarm, the company's selective androgen receptor modulator designed to preserve lean muscle mass when combined with GLP-1 receptor agonists such as Wegovy and Zepbound. The agency confirmed that the 3mg dosage of enobosarm is acceptable for future clinical development and outlined two potential pathways for approval based on incremental weight loss when added to GLP-1 therapy.
Under the first pathway, an incremental weight loss of at least 5% compared to GLP-1 treatment alone at 52 weeks would support efficacy approval. The second pathway would allow approval with less than 5% incremental weight loss if the combination demonstrates clinically meaningful benefits such as preserved physical function. The FDA also indicated that improving bone mineral density could serve as a primary endpoint, addressing emerging concerns that GLP-1 drugs may increase fracture risk.
Veru is advancing enobosarm as an adjunct therapy to address a critical limitation of current GLP-1 weight-loss medications: while effective at reducing body weight, these drugs can lead to significant loss of lean muscle mass. In the completed Phase 2b QUALITY study, patients receiving enobosarm plus semaglutide experienced a 71% relative reduction in lean mass loss compared to semaglutide alone. The 3mg dose proved most effective, with 99.1% of total weight loss attributed to fat rather than muscle.
"The successful completion of our FDA Type C meeting represents a major milestone for the enobosarm program," said Mitchell Steiner, chairman and chief executive officer of Veru. "The agency's guidance provides us with clear regulatory pathways to advance enobosarm in combination with GLP-1 receptor agonists for the treatment of obesity, with the potential to address critical unmet medical needs including preservation of lean mass, physical function, and bone health."
The upcoming PLATEAU trial will evaluate enobosarm 3mg in combination with tirzepatide in approximately 200 patients aged 65 and older with obesity. The 72-week study will assess incremental weight reduction, muscle preservation, physical function, and bone mineral density, with an interim analysis expected in the first quarter of 2027.
Analysts remain bullish on Veru's prospects despite the stock trading 57% below its 52-week high of $7.40. Shares currently hover around $2.30, giving the company a market capitalization of roughly $38 million. However, analysts maintain an average price target of $22.50, implying significant upside potential if enobosarm successfully navigates clinical development and regulatory approval.
Oppenheimer in August 2025 raised its price target to $25 from $4 while maintaining an Outperform rating, citing enobosarm's potential to differentiate itself in the crowded obesity market by addressing muscle preservation—a factor that could become increasingly important as GLP-1 therapies reach broader patient populations.
Veru's focus on the older obesity segment represents a strategic approach, as elderly patients are at higher risk for muscle loss and sarcopenia during rapid weight reduction. The PLATEAU trial's inclusion of physical function measures and bone density endpoints could position enobosarm as a comprehensive solution for healthy weight management in aging populations.
The company has pivoted its business strategy toward drug development following the divestiture of its FC2 Female Condom business, concentrating resources on enobosarm and sabizabulin, its oncology candidate. With $33 million in cash and a clearly defined regulatory pathway, Veru is positioned to execute on its clinical development plan over the next 18 months, with multiple data readouts that could catalyze the stock.